Phase 3 Findings Mark Progress in Relapsed or Refractory Multiple Myeloma Treatment

Bristol Myers Squibb (BMY) reported that Zenbexus met its primary goal in a Phase 3 trial for relapsed multiple myeloma, showing a 51% reduction in disease progression or death risk. The trial compared a 42-month median PFS for the Zenbexus combination to 20 months for standard care. BMY plans to share full results at the ASH Annual Meeting. The company reported FY2025 revenue of $48.2B, a slight decline, with net income of $7.1B.

Novartis and Bristol Myers Squibb paused CAR-T trials for autoimmune diseases due to safety concerns. Novartis halted rap-cel trials after three deaths from IEC-HS. Bristol Myers paused zola-cel enrollment after transient inflammatory events. Both companies are reviewing data with regulators.

Bristol Myers Squibb's (BMS) Zenbexus (iberdomide) met its primary endpoint in a Phase III trial, doubling progression-free survival (PFS) in multiple myeloma patients. The trial showed a median PFS of 42 months for Zenbexus compared to 20 months for standard therapy. The FDA approved Zenbexus for relapsed/refractory multiple myeloma in August 2026. BMS plans to present full results at the American Society of Hematology meeting in December.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 trial results for Zenbexus (iberdomide) in multiple myeloma patients. The drug, combined with daratumumab and dexamethasone, showed a 51% reduction in disease progression or death risk, with a median progression-free survival of 42 months. The FDA previously granted accelerated approval for Zenbexus in August. BMY shares were down 1.41% at $58.86 on Thursday.

Bristol Myers Squibb's Phase 3 EXCALIBER-RRMM study showed ZENBEXUS (iberdomide) with daratumumab and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma vs. standard care. The trial included 800 patients, with 16-month median follow-up. ZENBEXUS has accelerated approval for multiple myeloma treatment.

Bristol Myers Squibb reported positive results from a Phase 3 trial for Zenbexus, a treatment for multiple myeloma. The drug is already FDA-approved for another blood cancer. The trial success could expand Zenbexus's market potential.